Identification

Name
Trimethadione
Accession Number
DB00347  (APRD00315)
Type
Small Molecule
Groups
Approved
Description

An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

Structure
Thumb
Synonyms
  • Trimethadion
  • Triméthadione
  • Trimethadionum
  • Trimethinum
  • Troxidone
External IDs
A 2297 / J2.519D / NSC-15799 / NSC-169503
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TridioneTablet, chewable150 mg/1OralAbbvie1946-01-25Not applicableUs
International/Other Brands
Minoale (Dainippon Sumitomo) / Tridione
Categories
UNII
R7GV3H6FQ4
CAS number
127-48-0
Weight
Average: 143.1406
Monoisotopic: 143.058243159
Chemical Formula
C6H9NO3
InChI Key
IRYJRGCIQBGHIV-UHFFFAOYSA-N
InChI
InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
IUPAC Name
trimethyl-1,3-oxazolidine-2,4-dione
SMILES
CN1C(=O)OC(C)(C)C1=O

Pharmacology

Indication

Used in the control of absence (petit mal) seizures that are refractory to treatment with other medications.

Structured Indications
Pharmacodynamics

Paramethadione and trimethadione are anticonvulsants indicated in the control of absence (petit mal) seizures that are refractory to treatment with other medications. Dione anticonvulsants are used in the treatment of epilepsy. They act on the central nervous system (CNS) to reduce the number of seizures.

Mechanism of action

Dione anticonvulsants reduce T-type calcium currents in thalamic neurons, including thalamic relay neurons. It does so via the inhibition of voltage dependent T-type calcium channels. This raises the threshold for repetitive activity in the thalamus, and inhibits corticothalamic transmission. Thus, the abnormal thalamocortical rhythmicity, which is thought to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram(EEG) with absence seizures, is dampened.

TargetActionsOrganism
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

90%

Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include clumsiness or unsteadiness, coma, dizziness (severe), drowsiness (severe), nausea (severe), and problems with vision.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Trimethadione.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Trimethadione.Vet Approved
AbirateroneThe serum concentration of Trimethadione can be increased when it is combined with Abiraterone.Approved
Acetyl sulfisoxazoleThe metabolism of Trimethadione can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Trimethadione.Approved, Investigational
AmiodaroneThe metabolism of Trimethadione can be decreased when combined with Amiodarone.Approved, Investigational
AmobarbitalThe metabolism of Trimethadione can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Trimethadione.Approved, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Trimethadione.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Trimethadione.Approved, Investigational
ApalutamideThe serum concentration of Trimethadione can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Trimethadione can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe metabolism of Trimethadione can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Trimethadione.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Trimethadione.Approved
AtazanavirThe metabolism of Trimethadione can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Trimethadione can be decreased when combined with Atomoxetine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Trimethadione.Experimental
BarbexacloneThe metabolism of Trimethadione can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Trimethadione can be increased when combined with Barbital.Illicit
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Trimethadione.Approved, Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Trimethadione.Approved, Investigational
BoceprevirThe metabolism of Trimethadione can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Trimethadione can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Trimethadione can be decreased when it is combined with Bosentan.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Trimethadione.Experimental
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Trimethadione.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Trimethadione.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Trimethadione.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Trimethadione.Approved
Calcium AcetateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Trimethadione.Withdrawn
CapecitabineThe metabolism of Trimethadione can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Trimethadione.Experimental
CarbamazepineThe metabolism of Trimethadione can be increased when combined with Carbamazepine.Approved, Investigational
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Trimethadione.Approved, Investigational
CaseinThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Trimethadione.Approved
CelecoxibThe metabolism of Trimethadione can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Trimethadione can be increased when it is combined with Ceritinib.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Trimethadione.Approved
ChloramphenicolThe metabolism of Trimethadione can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Trimethadione.Approved
CholecalciferolThe metabolism of Trimethadione can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Trimethadione.Approved, Investigational
CimetidineThe serum concentration of Trimethadione can be increased when it is combined with Cimetidine.Approved, Investigational
CitalopramThe metabolism of Trimethadione can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Trimethadione can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Trimethadione can be decreased when combined with Clemastine.Approved, Investigational
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Trimethadione.Approved
ClotrimazoleThe metabolism of Trimethadione can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Trimethadione can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Trimethadione.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Trimethadione.Investigational
CrisaboroleThe metabolism of Trimethadione can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Trimethadione can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Trimethadione can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Trimethadione can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib.Approved, Investigational
DarunavirThe metabolism of Trimethadione can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Trimethadione can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Trimethadione can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Trimethadione can be decreased when combined with Delavirdine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Trimethadione.Vet Approved
DihydroergotamineThe metabolism of Trimethadione can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Trimethadione can be decreased when combined with Diltiazem.Approved, Investigational
DosulepinThe metabolism of Trimethadione can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Trimethadione.Approved
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Trimethadione.Approved, Investigational
DoxycyclineThe metabolism of Trimethadione can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Trimethadione can be decreased when combined with Dronedarone.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Trimethadione.Approved
EfavirenzThe serum concentration of Trimethadione can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Trimethadione.Approved
EnzalutamideThe serum concentration of Trimethadione can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Trimethadione can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
Eslicarbazepine acetateThe metabolism of Trimethadione can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Trimethadione can be decreased when combined with Esomeprazole.Approved, Investigational
EtravirineThe metabolism of Trimethadione can be decreased when combined with Etravirine.Approved
FelodipineThe metabolism of Trimethadione can be decreased when combined with Felodipine.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Trimethadione.Experimental
FloxuridineThe metabolism of Trimethadione can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Trimethadione can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Trimethadione.Approved, Investigational
FluorouracilThe metabolism of Trimethadione can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Trimethadione can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Trimethadione.Experimental
FluvastatinThe metabolism of Trimethadione can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Trimethadione can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Trimethadione can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Trimethadione can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Trimethadione can be increased when combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Trimethadione can be increased when it is combined with Fusidic Acid.Approved, Investigational
GemfibrozilThe metabolism of Trimethadione can be decreased when combined with Gemfibrozil.Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Trimethadione.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Trimethadione.Approved, Investigational, Vet Approved
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Trimethadione.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Trimethadione.Approved, Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Trimethadione.Approved, Investigational
HexobarbitalThe metabolism of Trimethadione can be increased when combined with Hexobarbital.Approved
IdelalisibThe metabolism of Trimethadione can be decreased when combined with Idelalisib.Approved
ImatinibThe metabolism of Trimethadione can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Trimethadione can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Trimethadione.Withdrawn
IrbesartanThe metabolism of Trimethadione can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Trimethadione can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Trimethadione can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Trimethadione.Approved
IsoniazidThe metabolism of Trimethadione can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Trimethadione can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Trimethadione can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Trimethadione can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Trimethadione can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Trimethadione.Approved
LapatinibThe metabolism of Trimethadione can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Trimethadione can be decreased when combined with Leflunomide.Approved, Investigational
LobeglitazoneThe metabolism of Trimethadione can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Trimethadione can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Trimethadione can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Trimethadione can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Trimethadione can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Trimethadione can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Trimethadione can be increased when it is combined with Lumacaftor.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Trimethadione can be decreased when combined with Manidipine.Approved, Investigational
MefloquineThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Mefloquine.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Trimethadione.Experimental
MethohexitalThe metabolism of Trimethadione can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Trimethadione can be increased when combined with Methylphenobarbital.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Trimethadione.Experimental
MianserinThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Mianserin.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Trimethadione.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Trimethadione.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Trimethadione can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Trimethadione can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Trimethadione.Approved, Investigational
MitotaneThe serum concentration of Trimethadione can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Trimethadione can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Trimethadione can be decreased when combined with Modafinil.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Trimethadione.Vet Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Trimethadione.Experimental
NabiloneThe metabolism of Trimethadione can be decreased when combined with Nabilone.Approved, Investigational
NafcillinThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Trimethadione.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Trimethadione.Approved
NefazodoneThe metabolism of Trimethadione can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Trimethadione can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Trimethadione can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Trimethadione can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Trimethadione can be decreased when combined with Nicardipine.Approved, Investigational
NicotineThe metabolism of Trimethadione can be decreased when combined with Nicotine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Trimethadione.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Trimethadione.Investigational
NilotinibThe metabolism of Trimethadione can be decreased when combined with Nilotinib.Approved, Investigational
NitroprussideTrimethadione may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Trimethadione.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Trimethadione.Approved, Vet Approved
OlaparibThe metabolism of Trimethadione can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Trimethadione can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Trimethadione.Experimental
OrlistatThe serum concentration of Trimethadione can be decreased when it is combined with Orlistat.Approved, Investigational
OsimertinibThe serum concentration of Trimethadione can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Trimethadione.Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Trimethadione.Investigational
PalbociclibThe serum concentration of Trimethadione can be increased when it is combined with Palbociclib.Approved, Investigational
PantoprazoleThe metabolism of Trimethadione can be decreased when combined with Pantoprazole.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Trimethadione.Approved, Investigational
PentobarbitalThe metabolism of Trimethadione can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Trimethadione can be increased when combined with Phenobarbital.Approved, Investigational
PhenytoinThe metabolism of Trimethadione can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Trimethadione can be decreased when combined with Pioglitazone.Approved, Investigational
PitolisantThe serum concentration of Trimethadione can be decreased when it is combined with Pitolisant.Approved, Investigational
PosaconazoleThe metabolism of Trimethadione can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Trimethadione.Approved
PregabalinThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrimidoneThe metabolism of Trimethadione can be increased when combined with Primidone.Approved, Vet Approved
PyrimethamineThe metabolism of Trimethadione can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Trimethadione.Experimental
QuinineThe metabolism of Trimethadione can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Trimethadione can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Trimethadione.Experimental
RanolazineThe metabolism of Trimethadione can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Trimethadione can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Trimethadione can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Trimethadione can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Trimethadione.Approved, Investigational
RosiglitazoneThe metabolism of Trimethadione can be decreased when combined with Rosiglitazone.Approved, Investigational
RucaparibThe metabolism of Trimethadione can be decreased when combined with Rucaparib.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Trimethadione.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Trimethadione.Approved, Investigational, Vet Approved
SaquinavirThe metabolism of Trimethadione can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Trimethadione can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Trimethadione.Approved, Investigational
SertralineThe metabolism of Trimethadione can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Trimethadione can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Trimethadione.Approved
SiltuximabThe serum concentration of Trimethadione can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Trimethadione can be increased when it is combined with Simeprevir.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Trimethadione.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Trimethadione.Approved, Investigational
SorafenibThe metabolism of Trimethadione can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Trimethadione can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Trimethadione can be increased when it is combined with Stiripentol.Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Trimethadione.Approved
SulfadiazineThe metabolism of Trimethadione can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Trimethadione can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Trimethadione can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TamoxifenThe metabolism of Trimethadione can be decreased when combined with Tamoxifen.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Trimethadione.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Trimethadione.Approved, Investigational
TelaprevirThe metabolism of Trimethadione can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Trimethadione can be decreased when combined with Telithromycin.Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Trimethadione.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Trimethadione.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Trimethadione.Approved
TeriflunomideThe metabolism of Trimethadione can be decreased when combined with Teriflunomide.Approved
ThiamylalThe metabolism of Trimethadione can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Trimethadione can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Trimethadione.Approved
TicagrelorThe metabolism of Trimethadione can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Trimethadione can be decreased when combined with Ticlopidine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Trimethadione.Approved
TocilizumabThe serum concentration of Trimethadione can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Trimethadione can be decreased when combined with Tolbutamide.Approved, Investigational
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Trimethadione.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Trimethadione.Approved, Investigational, Vet Approved
TopiramateThe metabolism of Trimethadione can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Trimethadione can be decreased when combined with Topiroxostat.Approved, Investigational
TranylcypromineThe metabolism of Trimethadione can be decreased when combined with Tranylcypromine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Trimethadione.Experimental
TrimethoprimThe metabolism of Trimethadione can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Trimethadione.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Trimethadione.Investigational
Valproic AcidThe metabolism of Trimethadione can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Trimethadione can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Trimethadione can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Trimethadione can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Trimethadione can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Trimethadione can be decreased when combined with Voriconazole.Approved, Investigational
ZafirlukastThe metabolism of Trimethadione can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Trimethadione can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Trimethadione can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014491
KEGG Drug
D00392
PubChem Compound
5576
PubChem Substance
46504478
ChemSpider
5374
BindingDB
50019167
ChEBI
9727
ChEMBL
CHEMBL695
Therapeutic Targets Database
DAP001265
PharmGKB
PA164744924
Drugs.com
Drugs.com Drug Page
Wikipedia
Trimethadione
ATC Codes
N03AC02 — Trimethadione

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Abbott laboratories pharmaceutical products div
Packagers
  • Abbott Laboratories Ltd.
Dosage forms
FormRouteStrength
Tablet, chewableOral150 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)46 °CPhysProp
water solubility5E+004 mg/LMERCK INDEX (1996)
logP0Not Available
Predicted Properties
PropertyValueSource
Water Solubility212.0 mg/mLALOGPS
logP0.07ALOGPS
logP0.5ChemAxon
logS0.17ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.61 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity33.2 m3·mol-1ChemAxon
Polarizability13.59 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9479
Caco-2 permeable+0.5287
P-glycoprotein substrateNon-substrate0.8304
P-glycoprotein inhibitor INon-inhibitor0.6154
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9503
CYP450 2C9 substrateNon-substrate0.8289
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5881
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9694
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9361
Ames testNon AMES toxic0.6493
CarcinogenicityNon-carcinogens0.8515
BiodegradationNot ready biodegradable0.7859
Rat acute toxicity1.8563 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Non-inhibitor0.9775
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.69 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4l-8900000000-43db0866b0f6797cbff6
GC-MS Spectrum - CI-BGC-MSsplash10-0006-1900000000-5560efcfc7260e1dcfef
Mass Spectrum (Electron Ionization)MSsplash10-0006-9200000000-46082deb9c636fb8f625
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxazolidinediones. These are compounds containing an oxazolidine ring which bears two ketones.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Oxazolidines
Direct Parent
Oxazolidinediones
Alternative Parents
Dicarboximides / Carbamate esters / Organic carbonic acids and derivatives / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Oxazolidinedione / Dicarboximide / Carbamic acid ester / Carbonic acid derivative / Oxacycle / Azacycle / Carboxylic acid derivative / Hydrocarbon derivative / Organopnictogen compound / Organic oxygen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Shen H, Zhang B, Shin JH, Lei D, Du Y, Gao X, Wang Q, Ohlemiller KK, Piccirillo J, Bao J: Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. Epub 2006 Dec 31. [PubMed:17291698]
  4. Barton ME, Eberle EL, Shannon HE: The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol. 2005 Oct 3;521(1-3):79-85. Epub 2005 Sep 19. [PubMed:16171802]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673]
  3. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673]
  3. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673]
  3. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]

Drug created on June 13, 2005 07:24 / Updated on May 01, 2018 22:09